EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Adjuvant Pembrolizumab after Upfront Multimodal Therapy for Stage IVB Anaplastic Thyroid Cancer

Maria E Cabanillas iD, Naifa L Busaidy, G Brandon Gunn, Priyanka C Iyer, Renata Ferrarotto, Maria Gule-Monroe, Anastasios Maniakas iD, Michelle D Williams, Suyu Liu, Bryan Fellman, Michael Spiotto, Sarah Hamidi iD und 7 weitere

Thyroid® · 01.07.2025 · 35 (7) · 763-770

DOI: 10.1089/thy.2025.0194 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Thyroid®, erschienen am 01.07.2025. Verfasst von Maria E Cabanillas und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, Texas, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedThyroid Carcinoma, AnaplasticThyroid NeoplasmsAntineoplastic Agents, ImmunologicalHumansMiddle AgedFemaleMaleAgedRetrospective StudiesCombined Modality TherapyAdultChemotherapy, AdjuvantNeoplasm StagingProspective Studies

Stichwörter der Autor:innen

chemotherapyimmunotherapylocoregional diseaseradiationundifferentiated

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, Texas, USA.
  • Department of Radiation Oncology, The University of Texas MD Anderson Cancer, Houston, Texas, USA.
  • Department of Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer, Houston, Texas, USA.
  • Department of Neuroradiology, The University of Texas MD Anderson Cancer, Houston, Texas, USA.
  • Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer, Houston, Texas, USA.
  • Department of Pathology, The University of Texas MD Anderson Cancer, Houston, Texas, USA.

ORCID-Profile: Maria E Cabanillas, Anastasios Maniakas, Sarah Hamidi, Jennifer R Wang, Vicente R Marczyk, Mark Zafereo

Zitieren

APA

Cabanillas, M. E., Busaidy, N. L., Gunn, G. B., Iyer, P. C., Ferrarotto, R., Gule-Monroe, M., Maniakas, A., Williams, M. D., Liu, S., Fellman, B., Spiotto, M., Hamidi, S., Akhave, N., Lee, A., Wang, J. R., de Sousa, L., Marczyk, V. R., Zafereo, M., & Dadu, R. (2025). Adjuvant Pembrolizumab after Upfront Multimodal Therapy for Stage IVB Anaplastic Thyroid Cancer. Thyroid®, 35(7), 763-770. https://doi.org/10.1089/thy.2025.0194

Vancouver

Cabanillas ME, Busaidy NL, Gunn GB, Iyer PC, Ferrarotto R, Gule-Monroe M, et al. Adjuvant Pembrolizumab after Upfront Multimodal Therapy for Stage IVB Anaplastic Thyroid Cancer. Thyroid®. 2025;35(7):763-770. doi:10.1089/thy.2025.0194

BibTeX
@article{Cabanillas2025,
  author = {Cabanillas, Maria E and Busaidy, Naifa L and Gunn, G Brandon and Iyer, Priyanka C and Ferrarotto, Renata and Gule-Monroe, Maria and Maniakas, Anastasios and Williams, Michelle D and Liu, Suyu and Fellman, Bryan and Spiotto, Michael and Hamidi, Sarah and Akhave, Neal and Lee, Anna and Wang, Jennifer R and de Sousa, Luana and Marczyk, Vicente R and Zafereo, Mark and Dadu, Ramona},
  title = {Adjuvant Pembrolizumab after Upfront Multimodal Therapy for Stage IVB Anaplastic Thyroid Cancer},
  journal = {Thyroid®},
  year = {2025},
  volume = {35},
  number = {7},
  pages = {763--770},
  doi = {10.1089/thy.2025.0194}
}
Kostenlos starten →